Norgine Completes Acquisition of Theravia

Norgine, a company with a long-standing history in the pharmaceutical and consumer health space, has finalized the acquisition of Theravia, an international pharmaceutical company dedicated to treating patients with rare and debilitating diseases. This acquisition underscores Norgine's ambition to deliver life-altering medications to patients with unmet medical needs. With the transaction now complete, Norgine plans to implement a structured integration process to harmonize operations, systems, and teams. The integration of Theravia strengthens Norgine's growing portfolio of rare disease medications and marks a crucial stage in its expansion strategy. Norgine's General Manager, Janneke van der Kamp, emphasized the importance of extending product access to markets where medical needs are significant and unmet, specifically targeting Europe, Australia, and New Zealand. As a wholly-owned subsidiary, Theravia will operate under Norgine's agile and innovative framework, which combines strong commercial capabilities with extensive medical, regulatory, and clinical expertise.